News

Podcast

Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS

Author(s):

Pearl Steinzor

Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.

Nathan Walcker

Nathan Walcker

Florida Cancer Specialists & Research Institute's (FCS') Nathan Walcker, CEO, discusses some key strategic practices and initiatives in providing high quality community-based oncology care he has implemented at FCS.

He spoke with us at The American Journal of Managed Care®’s Institute for Value-Based Medicine® event held in Tampa, Florida, on August 10, 2023.

Listen above or through one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify


Related Videos
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Elizabeth Grush, MBA
Raj Chovatiya, MD, PhD, MSCI.
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Erin Weber, MS
Lynae Darbes, PhD
Kenny Cole, MD
Richard Lafayette, MD, FACP, Stanford University Medical Center
Related Content
In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com
April 15th 2025

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

Jared Kaltwasser
Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Center on Health Equity and Access
April 14th 2025

Health Equity & Access Weekly Roundup: April 14, 2025

Giuliana Grossi
From the potential impact of tariffs to the World Health Organization's year-long campaign launch focused on improving maternal and newborn health and addressing preventable deaths, here's the latest from the Center on Health Equity & Access.
Managed Care Cast Presents: Unlocking the Potential of CGM Technology
April 10th 2025

Managed Care Cast Presents: Unlocking the Potential of CGM Technology

Laura Joszt, MA
A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.
Experts Issue a Call to Action for Oncology Care Equity
April 13th 2025

Experts Issue a Call to Action for Oncology Care Equity

Maggie L. Shaw
Coverage from the Nashville Regional meeting of the Institute for Value-Based Medicine.
Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com
April 11th 2025

Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS

Mary Caffrey Caspian Oliai, MD, MS Rose McNulty
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo